My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Anales de Medicina Interna
Print version ISSN 0212-7199
Abstract
BONILLA HERNAN, Mª G.; COBO IBANEZ, T.; MIGUEL MENDIETA, E. de and MARTIN-MOLA, E.. Infliximab (anti-TNF alfa) in the treatment of adult Still’s disease: Two cases. An. Med. Interna (Madrid) [online]. 2004, vol.21, n.1, pp.23-26. ISSN 0212-7199.
Adult Still´s disease is a systemic inflammatory disorder of unknown etiolgy. First-line treatment for Still´s disease includes nonsteroidal anti-inflammatory drugs and corticosteroids. In refractory cases o when the dose of corticosteroid is unacceptbly high, other disease modifiying antirheumatic drugs have been used. But recent study showed the efficacy anti-TNF therapy in adult Sill´s disease refractory to conventional therapy We report a favourable response to infliximab in two patients who has proved resistant to conventional therapy.
Keywords : Adult Still´s disease; Infliximab; Anti-TNF-a treatment.